NCT07208773 - A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

December 31, 2027

Conditions

Advanced Solid TumorsNon Small Cell Lung CancerSmall Cell Lung Cancer

Interventions

DRUG

YL201

YL201 will be administered as IV infusion

DRUG

Ivonescimab

Ivonescimab will be administered as IV infusion.

Trial Locations (1)

Sun Yat-sen University Cancer Center, Guangzhou